MEK inhibitors (MAPKi), such as cobimetinib or trametinib, and immune checkpoint inhibitors such as atezolizumab are used in clinic in combination with BRAF inhibitors to delay the onset of drug-resistant tumor outgrowth [3, 4]. The gene discussed is BRAF; the disease is neoplasm.